
PRODUCT INFORMATION

NGI-189

Item No. 46103

CAS Registry No.:	2763063-26-7
Formal Name:	2-(cyclopentylmethylamino)-N-(5-ethyl-2-thiazolyl)-5-(4-morpholinylsulfonyl)-benzamide
MF:	$C_{22}H_{30}N_4O_4S_2$
FW:	478.6
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

NGI-189 is supplied as a solid. A stock solution may be made by dissolving the NGI-189 in the solvent of choice, which should be purged with an inert gas. NGI-189 is slightly soluble (0.1-1 mg/ml) in ethanol and sparingly soluble (1-10 mg/ml) in DMSO.

Description

NGI-189 is an oligosaccharyltransferase A (OST-A) complex inhibitor and a derivative of NGI 1 (Item No. 31519).[1] It inhibits the glycosylation of an endoplasmic reticulum reporter protein in cells (IC_{50} = 90 nM) and selectively inhibits the glycosylation of EGFR in *STT3A* knockout HEK293 cells over *STT3B* knockout HEK293 cells, which lack expression of the OST-A and OST-B catalytic subunits, respectively. NGI-189 inhibits EGFR glycosylation in, and the survival of, NCI H3255, HCC4006, and HCC2935 non-small cell lung cancer (NSCLC) cells expressing $EGFR^{L858R}$, $EGFR^{\Delta747\text{-}749/A750P}$, or $EGFR^{\Delta746\text{-}751/S752I}$, respectively. It induces cell cycle arrest at the G_1 phase and reduces the proliferation of PC-9 NSCLC cells expressing the activating $EGFR^{\Delta746\text{-}750}$ mutation. NGI-189 (10 mg/kg, i.p.) reduces tumor growth in patient-derived xenograft (PDX) mouse models of NSCLC containing EGFR-activating mutations.

Reference

1. Baro, M., Lee, H., Kelley, V., *et al*. Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. *Cell Chem. Biol*. **32(6)**, 839-853.e6 (2025).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/02/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM